CMP Pharma Consumer Health Data Privacy Policy

Nov 2026

1. What this policy covers

This Consumer Health Data Privacy Policy explains how CMP Pharma, Inc. (“CMP,” “we,” “us”) collects, uses and shares consumer health data through www.cmppharma.com, our product websites, our co-pay savings pages and our Living With Dysphagia page (together, the “Sites”). It supplements, and does not replace, our Privacy Policy and applies to residents of Washington, Nevada and Connecticut and to anyone whose consumer health data is collected in those states.

“Consumer health data” means personal information that is linked or reasonably linkable to you and that identifies your past, present or future physical or mental health status. On our Sites this includes information you enter into a co-pay savings or patient-support form, and inferences about your health interests that could be drawn from your visits to pages about a medical condition or a prescription product.

This policy does not cover protected health information governed by HIPAA, de-identified data, or information we hold about healthcare providers in their professional capacity.

2. Consumer health data we collect and why

We collect only the consumer health data listed below, and only for the purposes listed. We do not collect, use or share consumer health data for any other purpose without first asking for your consent.

CategoryExamplesPurpose
Co-pay savings enrollment dataName, date of birth, contact details, the CMP product prescribed, insurance type, pharmacy and prescriber information [confirm fields with co-pay vendor]To enroll you in, administer and verify eligibility for the co-pay savings program; to detect fraud; to meet program and legal reporting requirements
Information you send usHealth or treatment details you include in a message, medical-information request, adverse-event report or product complaintTo respond to you and to meet FDA and other safety and regulatory reporting obligations
Health inferences from Site usePages viewed (for example, a condition page or product page), time on page, clicks, referral source, IP address and device identifiers, where these could reveal a health interestTo operate, secure and improve the Sites; to measure how content is used; and, only with your opt-in through the cookie banner, for analytics and marketing

We do not use session-replay or advertising tools on pages that discuss medical conditions or our co-pay program, and we do not use biometric data, precise geolocation or geofencing in connection with health care facilities.

3. Where the data comes from

  • You, when you complete a co-pay savings form, contact us, or report a side effect or product complaint.
  • Your device and browser, through cookies, pixels and similar technologies, as described in our Privacy Policy and controlled through our cookie banner. Non-necessary cookies load only after you choose “Accept All.”
  • Our co-pay program administrator, which may confirm your enrollment, claims and eligibility to us [confirm with vendor contract].
  • Pharmacies, prescribers and insurers, only to the extent needed to process a co-pay claim you submitted.

We do not buy consumer health data from data brokers and we do not combine Site browsing data with co-pay enrollment data to build health profiles.

4. How we sell consumer health data

We do not sell consumer health data, and we will not do so without your separate, signed authorization. We share it only as follows:

Who we share withWhatWhy
Co-pay program administrator and claims processorsCo-pay enrollment and claims dataTo run the program on our behalf under contracts that limit use to our instructions
Website hosting, security and analytics providersTechnical and Site-interaction data that may reveal a health interestTo host, secure and measure the Sites; analytics only with your opt-in
CMP affiliatesAny category aboveFor the purposes in Section 2
Regulators and safety-reporting bodies (for example, FDA)Adverse-event and product-complaint informationTo meet legal reporting duties
Legal, compliance and professional advisorsAs needed for the matterTo obtain advice, respond to lawful requests and protect legal rights

We do not share consumer health data with third-party advertisers. Where our general Privacy Policy allows disclosure to advertising partners, that disclosure excludes consumer health data.

5. Your rights and how to exercise them

You have the right to:

  • Confirm whether we collect, share or sell your consumer health data and access it.
  • Receive a list of the third parties and affiliates with which we have shared or sold it, with their email address or other online contact.
  • Withdraw consent to our collection or sharing of your consumer health data.
  • Delete your consumer health data, including from our systems, backups and the service providers we share it with.

To make a request, email compliance@cmppharma.com or call 1-800-227-6637. We will confirm your request and respond within 45 days; we may extend once by 45 days and will tell you if so. We may ask for information to verify your identity. An authorized agent may act for you if they can show your authorization.

If we deny your request, you may appeal by emailing compliance@cmppharma.com with “Consumer Health Data Appeal” in the subject line. We will respond within 45 days. If your appeal is denied, you may contact your state Attorney General. In Washington, this can be done at www.atg.wa.gov, in Nevada at ag.nv.gov, and in Connecticut at portal.ct.gov/ag.

We will not discriminate against you for exercising these rights.

6. Changes and contact

Effective date: November 2026. If we change how we collect or share consumer health data, we will update this policy and, where the law requires, ask for your consent before applying the change to data we already hold.

CMP Pharma, Inc., 8026 East Marlboro Road, Farmville, North Carolina 27828 · compliance@cmppharma.com · 1-800-227-6637

Important Safety Information

Full Prescribing Information

Indications and Usage

NORLIQVA is a calcium channel blocker for the treatment of:

HYPERTENSION
NORLIQVA is indicated for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

CORONARY ARTERY DISEASE

  • Chronic Stable Angina
  • Vasospastic Angina (Prinzmetal’s or Variant Angina)
  • Angiographically Documented Coronary Artery Disease In patients without heart failure or an ejection fraction <40%

Contraindications

NORLIQVA is contraindicated in patients with sensitivity to amlodipine.

Warnings and Precautions

NORLIQVA may cause the following conditions.

  • Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely.
  • Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of NORLIQVA, particularly in patients with severe obstructive coronary artery disease.
  • Titrate slowly in patients with severe hepatic impairment.

Adverse Reactions

Most common adverse reactions to amlodipine were edema, dizziness, flushing and palpitation which occurred in a dose related manner. Other adverse reactions not clearly dose-related but reported with an incidence >1.0% are fatigue and nausea.

See full Prescribing Information for other possible side effects with NORLIQVA. To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

Do not exceed doses greater than 20 mg daily of simvastatin.

  • CYP3A Inhibitors: Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.
  • CYP3A Inducers: No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.
  • Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.
  • Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.

Dosage and Administration

NORLIQVA is an oral solution: 1 mg/mL. Adult recommended starting dose: 5 mg orally once daily with a maximum of 10 mg orally once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg orally once daily. Pediatric starting dose: 2.5 mg to 5 mg orally once daily.

Please see full Prescribing Information for additional safety information.

You are now leaving norliqva.com.

You are about to go to a website that is not owned or controlled by CMP Pharma, Inc. CMP Pharma is not responsible for the content, accuracy, or privacy practices of that site, and providing this link does not mean CMP Pharma endorses it. The site may contain information about uses of products that have not been approved by the FDA.

Continue